DOCSLIB.ORG

Paliperidone Long Acting Injection (Xeplion )

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paliperidone Long Acting Injection (Xeplion ) Paliperidone Long Acting Injection (Xeplion®) Guidance for Prescribing and Administration Main points 1. Paliperidone Long Acting Injection (Paliperidone LAI) is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone (Note – oral paliperidone is a non-formulary drug in the AWP Trust formulary). In selected adult patients with schizophrenia and previous responsiveness to oral risperidone (or paliperidone), paliperidone LAI may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed. 2. Paliperidone LAI is not indicated for treatment-resistant schizophrenia, unlicensed indications (e.g. schizoaffective disorder, bipolar, personality disorder) or patients intolerant to oral risperidone or paliperidone. 3. Paliperidone LAI may ONLY be newly prescribed by consultant psychiatrists. Other grades may initiate, but ONLY with direct instruction from their consultant. 4. Risperidone LAI should no longer be initiated for new patients. For those patients who have shown a response to oral risperidone (or paliperidone) with no ADRs and where a LAI is required, paliperidone LAI should be considered in the first instance. 5. Those patients who are stable on risperidone LAI, should remain on RLAI unless there is a need to switch. 6. Paliperidone LAI is intended for once-monthly injection (i.e. once per calendar month, not 4-weekly), by intramuscular (IM) injection into the deltoid or gluteal muscle. However, the loading doses must be given into the deltoid muscle. (See below). 7. Switching from an oral antipsychotic: Paliperidone LAI initiated with 150 mg on day 1 and 100 mg on day 8.in the deltoid muscle to attain therapeutic concentrations rapidly. Oral supplementation should not be required. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. Target maintenance dose is 75mg per month. 8. Switching from risperidone or olanzapine long acting injection or traditional depot: No loading dose is needed or oral supplementation. Paliperidone LAI should be initiated in place of the next scheduled injection. Paliperidone LAI should then be continued at monthly intervals. 9. Paliperidone LAI is very expensive when compared to traditional antipsychotic depots and is also more expensive than risperidone LAI in terms of procurement costs. PLAI is more costly than aripiprazole LAI. At 100mg per month (equivalent to risperidone consta 50mg per fortnight), it costs ~ £3.800 per patient per year. For cost comparisons, see Appendix 1. 10. Practical comparisons with aripiprazole and risperidone LAI are given in Appendix 2. 11. For ‘Place in therapy’, please see next section. Prescribing guidelines Paliperidone LAI May 2014 V1.0 BLS Final Place in therapy The following criteria should be fulfilled BEFORE Paliperidone LAI is prescribed: a) Documented ICD – 10 diagnosis for *schizophrenia. b) Dosing schedule will be followed as per SPC c) Service user has been on oral risperidone or risperidone consta with proven response and tolerability. d) Been on 2 or fewer antipsychotics i.e. not treatment resistant when service user should be on clozapine. *if used for unlicensed indication, the ‘Procedure for unlicensed /off label medicines’ must be followed. Switching from an antipsychotics other than oral risperidone or risperidone LAI to paliperidone LAI should only occur if: a) current treatment is ineffective b) adverse side-effect profile caused by current treatment excluding metabolic disturbance/ weight gain / cardiac effects / raised prolactin. If these apply, consider Aripiprazole LAI. c) there are adherence issues with current treatment (so monthly injections preferred). d) the service user prefers LAI to oral (i.e. convenience) e) the service user prefers deltoid administration (& RLAI less preferred) f) Where higher doses are needed (150mg) & staying within licensed (75mg RLAI is unlicensed) g) Some patient groups e.g. community patients, where missed dosing is less of an issue as PLAI allows more flexible dosing (unlike RLAI). Service users stabilised on Risperidone Consta (or other LAI / depot antipsychotic) should NOT be switched as this will carry a risk of destabilisation and hence relapse. When paliperidone LAI is prescribed for outpatients, it may be obtained from polar speed which is VAT exempt and will save the Trust money. Please ask your locality pharmacist if you require support setting this up. To avoid a missed dose, service users may be given the second dose 4 days before or after the one-week (day 8) time point. Similarly, the third and subsequent injections after the initiation regimen are recommended to be given monthly. To avoid a missed monthly dose, patients may be given the injection up to 7 days before or after the monthly time point. Prescribing regimes Switching form oral antipsychotics: Patients should be stabilised on oral risperidone (or oral paliperidone), or have shown previous responsiveness to one of them. If not, it is recommended they be stabilised on oral risperidone prior to initiating treatment with paliperidone LAI. (Note: Oral paliperidone is non- formulary and is not in the Trust formulary). Switch from oral risperidone (or oral paliperidone) to paliperidone LAI by replacing the oral drug with an initiation dose of LAI on day 1. This should be followed with a second initiation dose on day 8 as described below. Day 1 - 150mg into the deltoid muscle. Day 8 (+/- 4 days) - 100mg into the deltoid muscle. Prescribing guidelines Paliperidone LAI May 2014 V1.0 BLS Final Day 36 (+/- 7 days) - Maintenance dose into deltoid or gluteal muscle Switching from risperidone LAI: Administer the equivalent dose of paliperidone LAI at the time the next scheduled risperidone LAI is due: Current dose of RLAI: Switch to: Risperidone LAI dose Paliperidone LAI dose 25mg every 2 weeks 50mg monthly 37.5mg every 2 weeks 75mg monthly 50mg every 2 weeks 100mg monthly Frequency changes from two-weekly to once per calendar month. Switching from traditional depot injections (There is no specific SPC guidance for this, but advice is taken from information from company). Administer the paliperidone LAI dose at the time the next scheduled traditional depot injection is due. However, note that it is not possible to accurately determine 'dose equivalents' between paliperidone and traditional depot injections, therefore the choice of dose should be based on clinical experience and individual patient assessment. It is suggested that the dose does not initially exceed 75mg, and that the patient is very closely monitored, both for response and for adverse effects. The recommended maintenance dose is 75mg per month although some patients may benefit from lower or higher doses, within the range 50mg to 100mg, based on efficacy and tolerability. A maximum maintenance dose of 150mg per month is also available and within the terms of the Product Licence. This dose is equivalent to 75mg risperidone Consta® 2-weekly and should only be prescribed when absolutely necessary as is very costly. Other Dosing Recommendations / Considerations: a) The elderly: Efficacy and safety in patients over 65 years of age have not been established. If used, lower doses should be considered particularly if renal function is diminished. The product has not been studied in elderly patients with dementia and should not be used. b) Children & Adolescents: The product is not licensed for use in patients less than 18 c) years of age. No efficacy or safety data are available. d) Renal impairment: Lower loading and maintenance doses should be used. Manufacturer’s data should be referred to before prescribing or ask your Locality Pharmacist for advice. e) Hepatic impairment: No dosage adjustment is required in mild or moderate impairment. Use in severe impairment should be avoided. Prescribing guidelines Paliperidone LAI May 2014 V1.0 BLS Final Administration Paliperidone LAI is licensed as a once monthly injection i.e. maintenance dose to be administered 12 times a year – one per calendar month NOT 4-weekly administration as this means the service user will receive maintenance dose 13 times a year, which will NOT provide any greater efficacy but will greatly increase costs. Following administration of paliperidone LAI there is no requirement for any enhanced level of patient monitoring. Patients should be monitored for post-injection events in the same way as for risperidone LAI or for traditional depot injections. Storage Paliperidone LAI should be stored in a locked medicines cabinet; there is no requirement for fridge storage. Paliperidone LAI is supplied in pre-filled syringes; there is no need for any reconstitution or dilution. Only full syringe doses may be used as the dose administered from less than a full syringe cannot be assured. Prescribing guidelines Paliperidone LAI May 2014 V1.0 BLS Final Appendix 1: Cost comparison of Long-Acting Injections (LAI) and depots (Drug Tariff March 2014) Name Dose Cost per unit Cost per year Paliperidone LAI 50mg monthly £ 183.92 x 12 £ 2207.04 75mg monthly £ 244.90 x 12 £ 2938.80 100mg monthly £ 314.07 x 12 £ 3768.84 150mg monthly £ 392.59 x 12 £ 4711.08 Risperidone LAI 25mg 2- weekly £ 79.69 x 26 £ 2071.94 37.5mg 2-weekly £111.32 x 26 £ 2894.32 50mg 2-weekly £142.76 x 26 £ 3711.76 Olanzapine LAI 150mg 2- weekly £ 142.76 x 26 3711.76 300mg 4-weekly £ 222.64 x13 2894.32 210mg 2-weekly £ 142.76 x 26 3711.76 405mg 4-weekly £ 285.52 x 13 3711.76 300mg 2 weekly £ 222.64 x 26 5788.64 Aripiprazole LAI 400mg monthly £ 220.41 x 12 £ 2644.92 Traditional depot antipsychotics: Flupentixol 200mg every 2 weeks £19.52 x 26 £ 507.52 (200mg/mL) Fluphenazine 100mg every 2 weeks £8.79 x 26 £ 228.54 (100mg/mL) Haloperidol 200mg every 4 weeks £10.10 x 13 £ 131.30 (100mg/mL x 2) Pipotiazine 200mg every 4 weeks £53.30 x 13 £ 692.90 (50mg/mL.2x2mL amp) Zuclopenthixol 500mg every 2 weeks £7.44 x 26 £ 193.44 (500mg/mL) **a loading dose for PLAI may not always be necessary if switching from RLAI or depot.
Load more

Recommended publications
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • Paliperidone Long Acting Injection Patient Information
    Paliperidone (pala-pera-done) long acting injection Patient Information - Hillmorton Hospital Pharmacy www.healthinfo.org.nz Why have I been prescribed paliperidone? Paliperidone is used to treat schizophrenia, psychosis and similar conditions. It can also be used to treat mania. A person diagnosed with schizophrenia may hear voices talking to them or about them. They may also become suspicious or paranoid. Some people also have problems with their thinking and feel that other people can read their thoughts. These are called “positive Paliperidone Injection Long Acting symptoms”. Paliperidone can help to relieve these symptoms. Many people with schizophrenia also experience “negative symptoms”. They feel tired and lacking in energy and may become quite inactive and withdrawn. Paliperidone may help relieve these symptoms as well. Paliperidone may also be prescribed for people who have had side effects such as strange movements and shaking, with older types of antipsychotics. Paliperidone is a close relative of the antipsychotic risperidone. It’s side effect profile is similar but has the advantage of being able to be given as a once a month injection. What exactly is paliperidone? Is paliperidone safe for me? It is usually safe to take paliperidone Paliperidone is one of a group of regularly as prescribed by your doctor, but medicines used to treat schizophrenia it doesn’t suit everyone. Let your doctor and similar disorders. These illnesses are know if any of the following apply to you, sometimes referred to as psychoses, as extra care may be needed: hence the name given to this group of medicines, which is the “antipsychotics”.
    [Show full text]
  • Second-Generation Long-Acting Injectable Antipsychotics: a PRACTICAL GUIDE Understanding Each of These Medications’ Unique Properties Can Optimize Patient Care
    Second-generation long-acting injectable antipsychotics: A PRACTICAL GUIDE Understanding each of these medications’ unique properties can optimize patient care Brittany L. Parmentier, PharmD, MPH, here are currently 7 FDA-approved second-generation long-acting BCPS, BCPP 1-7 Clinical Assistant Professor injectable antipsychotics (LAIAs). These LAIAs provide a Department of Pharmacy Practice Tunique dosage form that allows patients to receive an antipsy- The University of Texas at Tyler Fisch College of Pharmacy chotic without taking oral medications every day, or multiple times per Tyler, Texas day. This may be an appealing option for patients and clinicians, but Disclosure The author reports no financial relationships with any because there are several types of LAIAs available, it may be difficult to companies whose products are mentioned in this article, or with determine which LAIA characteristics are best for a given patient. manufacturers of competing products. Since the FDA approved the first second-generation LAIA, risperidone long-acting injectable (LAI),1 in 2003, 6 additional second-generation LAIAs have been approved: • aripiprazole LAI • aripiprazole lauroxil LAI • olanzapine pamoate LAI • paliperidone palmitate monthly injection • paliperidone palmitate 3-month LAI • risperidone LAI for subcutaneous (SQ) injection. When discussing medication options with patients, clinicians need to consider factors that are unique to each LAIA. In this article, I describe the similarities and differences among the second-generation LAIAs, and address common questions about these medications. A major potential benefit: Increased adherence One potential benefit of all LAIAs is increased medication adherence com- pared with oral antipsychotics. One meta-analysis of 21 randomized con- trolled trials (RCTs) that compared LAIAs with oral antipsychotics and Current Psychiatry GEORGE MATTEI/SCIENCE SOURCE GEORGE MATTEI/SCIENCE Vol.
    [Show full text]
  • INVEGA SUSTENNA® (Paliperidone Palmitate)
    INVEGA SUSTENNA® INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use (paliperidone palmitate) extended-release injectable suspension, for intramuscular use --------------------------- DOSAGE FORMS AND STRENGTHS --------------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION Extended-release injectable suspension: 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, These highlights do not include all the information needed to use 156 mg/mL, or 234 mg/1.5 mL (3) INVEGA SUSTENNA® safely and effectively. See full prescribing information for INVEGA SUSTENNA®. ----------------------------------- CONTRAINDICATIONS ----------------------------------- INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable Known hypersensitivity to paliperidone, risperidone, or to any excipients in suspension, for intramuscular use INVEGA SUSTENNA®. (4) Initial U.S. Approval: 2006 -----------------------------WARNINGS AND PRECAUTIONS ----------------------------- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with WITH DEMENTIA-RELATED PSYCHOSIS Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse See full prescribing information for complete boxed warning. reactions (e.g. stroke, transient ischemic attack). (5.2) • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of Elderly patients with dementia-related psychosis treated with antipsychotic drug and close monitoring. (5.3) drugs are
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
    pharmaceutics Review Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics Francisco José Toja-Camba 1,2,† , Nerea Gesto-Antelo 3,†, Olalla Maroñas 3,†, Eduardo Echarri Arrieta 4, Irene Zarra-Ferro 2,4, Miguel González-Barcia 2,4 , Enrique Bandín-Vilar 2,4 , Victor Mangas Sanjuan 2,5,6 , Fernando Facal 7,8 , Manuel Arrojo Romero 7, Angel Carracedo 3,9,10,* , Cristina Mondelo-García 2,4,* and Anxo Fernández-Ferreiro 2,4,* 1 Pharmacy Department, University Clinical Hospital of Ourense (SERGAS), Ramón Puga 52, 32005 Ourense, Spain; [email protected] 2 Clinical Pharmacology Group, Institute of Health Research (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain; [email protected] (I.Z.-F.); [email protected] (M.G.-B.); [email protected] (E.B.-V.); [email protected] (V.M.S.) 3 Genomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; [email protected] (N.G.-A.); [email protected] (O.M.) 4 Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Citation: Toja-Camba, F.J.; 15706 Santiago de Compostela, Spain; [email protected] Gesto-Antelo, N.; Maroñas, O.; 5 Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Echarri Arrieta, E.; Zarra-Ferro, I.; 46100 Valencia, Spain González-Barcia, M.; Bandín-Vilar, E.; 6 Interuniversity Research Institute for Molecular Recognition and Technological Development,
    [Show full text]
  • Invega (Paliperidone)
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use • Tardive Dyskinesia: Discontinue drug if clinically appropriate (5.5) INVEGA® safely and effectively. See full prescribing information for • Hyperglycemia and Diabetes Mellitus: Monitor glucose regularly in INVEGA®. patients with and at risk for diabetes (5.6) • Hyperprolactinemia: Prolactin elevations occur and persist during chronic INVEGA® (paliperidone) Extended-Release Tablets administration (5.7) Initial U.S. Approval: 2006 • Gastrointestinal Narrowing: Obstructive symptoms may result in patients with gastrointestinal disease (5.8) WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Orthostatic Hypotension and Syncope: Use with caution in patients with WITH DEMENTIA-RELATED PSYCHOSIS known cardiovascular or cerebrovascular disease and patients See full prescribing information for complete boxed warning. predisposed to hypotension (5.9) Elderly patients with dementia-related psychosis treated with • Leukopenia, Neutropenia, and Agranulocytosis: has been reported with ® antipsychotic drugs are at an increased risk of death. INVEGA is not antipsychotics, including INVEGA®. Patients with a history of a approved for use in patients with dementia-related psychosis. (5.1) clinically significant low white blood cell count (WBC) or a drug- induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and ----------------------------RECENT MAJOR CHANGES--------------------------
    [Show full text]
  • Invega Paliperidone
    EMA/529190/2017 EMEA/H/C/000746 EPAR summary for the public Invega paliperidone This is a summary of the European public assessment report (EPAR) for Invega. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Invega. For practical information about using Invega, patients should read the package leaflet or contact their doctor or pharmacist. What is Invega and what is it used for? Invega is an antipsychotic medicine used in adults and adolescents from 15 years of age to treat schizophrenia, a mental illness with symptoms such as disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs). Invega is also used to treat adults with schizoaffective disorder. This is a condition in which the patient has episodes of elevated mood (mania) or low mood (depression) in addition to symptoms of schizophrenia. Invega contains the active substance paliperidone. How is Invega used? Invega can only be obtained with a prescription. It is available as prolonged-release tablets (3, 6, 9 and 12 mg). ‘Prolonged release’ means that paliperidone is released slowly from the tablet over a few hours. The recommended starting dose of Invega in adults is 6 mg once a day, taken in the morning; the starting dose in adolescents is 3 mg daily. Patients can take Invega either with food or between meals, but should not switch between taking it with food on one day and between meals on another.
    [Show full text]
  • Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults
    Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults Version 1 GUIDELINE NO RATIFYING COMMITTEE DRUGS AND THERAPEUTICS GROUP DATE RATIFIED April 2014 DATE AVAILABLE ON INTRANET NEXT REVIEW DATE April 2016 POLICY AUTHORS Nana Tomova, Clinical Pharmacist Dr Richard Whale, Consultant Psychiatrist In association with: Dr Gordon Caldwell, Consultant Physician, WSHT . If you require this document in an alternative format, ie easy read, large text, audio, Braille or a community language, please contact the Pharmacy Team on 01243 623349 (Text Relay calls welcome). Contents Section Title Page Number 1. Introduction 2 2. Causes of Hyperprolactinaemia 2 3. Antipsychotics Associated with 3 Hyperprolactinaemia 4. Effects of Hyperprolactinaemia 4 5. Long-term Complications of Hyperprolactinaemia 4 5.1 Sexual Development in Adolescents 4 5.2 Osteoporosis 4 5.3 Breast Cancer 5 6. Monitoring & Baseline Prolactin Levels 5 7. Management of Hyperprolactinaemia 6 8. Pharmacological Treatment of 7 Hyperprolactinaemia 8.1 Aripiprazole 7 8.2 Dopamine Agonists 8 8.3 Oestrogen and Testosterone 9 8.4 Herbal Remedies 9 9. References 10 1 1.0 Introduction Prolactin is a hormone which is secreted from the lactotroph cells in the anterior pituitary gland under the influence of dopamine, which exerts an inhibitory effect on prolactin secretion1. A reduction in dopaminergic input to the lactotroph cells results in a rapid increase in prolactin secretion. Such a reduction in dopamine can occur through the administration of antipsychotics which act on dopamine receptors (specifically D2) in the tuberoinfundibular pathway of the brain2. The administration of antipsychotic medication is responsible for the high prevalence of hyperprolactinaemia in people with severe mental illness1.
    [Show full text]
  • Mental Health Medications
    Mental Health Medications National Institute of Mental Health U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES UÊÊ >Ì>ÊÃÌÌÕÌiÃÊvÊi>Ì Contents Mental Health Medications ..............................................................1 What are psychiatric medications? .....................................................1 How are medications used to treat mental disorders? .......................................1 What medications are used to treat schizophrenia? ............................................2 What are the side effects? ............................................................2 How are antipsychotics taken and how do people respond to them? ...........................3 How do antipsychotics interact with other medications? ....................................3 What medications are used to treat depression? ..............................................4 What are the side effects? ............................................................4 How should antidepressants be taken? ..................................................5 Are herbal medicines used to treat depression? ...........................................5 FDA warning on antidepressants.......................................................6 What medications are used to treat bipolar disorder? . .7 Mood stabilizers ...................................................................7 Atypical antipsychotics ..............................................................7 Antidepressants ....................................................................7 What are the
    [Show full text]
  • Drug Class Review Atypical Antipsychotic Drugs
    Drug Class Review Atypical Antipsychotic Drugs Final Report Update 2 June 2008 Original Report Date: January 2005 Update 1 Report Date: April 2006 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Marian S. McDonagh, PharmD Kim Peterson, MS Susan Carson, MPH Benjamin Chan, MS Sujata Thakurta, MPA:HA Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION.............................................................................................................8 Scope and Key Questions ......................................................................................................15 METHODS .................................................................................................................... 18 Literature Search ....................................................................................................................18 Study Selection
    [Show full text]
  • Long-Acting Injectable (LAI) Dosing Chart
    Long-Acting Injectable (LAI) Dosing Chart Drug FDA-Approved Dosing Earliest Time to Missed Dose Indications Next Dose ABILIFY • Schizophrenia Initiation No sooner than 26 days If 2nd or 3rd dose missed: MAINTENA® • Maintenance 400 mg IM q month + aripiprazole 10-20 mg after last injection Timing of Missed Dose Dosing (aripiprazole)1 Monotherapy of PO daily x14 days OR if stable on another PO >4 weeks and <5 weeks • Administer missed dose ASAP. Bipolar 1 Disorder antipsychotic, + overlap x14 days >5 weeks • Restart next injection with oral Dosage Forms aripiprazole x 14 days. 300 mg and 400 mg Maintenance pre-filled syringe or 400 mg IM q month If 4th or subsequent doses missed: single-use vial Timing of Missed Dose Dosing Dose Adjustments >4 weeks and <6 weeks • Administer missed dose ASAP. Adverse reactions or known CYP2D6 poor >5 weeks • Restart next injection with oral metabolizers: aripiprazole x 14 days. 300 mg IM q month ARISTADA INITIO®, • Schizophrenia Initiation No sooner than 14 days ARISTADA® Option #1: ARISTADA INITIO® 675 mg IM x1 after last injection Management of a Missed Maintenance Dose (aripiprazole dose + aripiprazole 30 mg PO x1 dose + first Last Time Since Last Injection lauroxil)2,3 dose of *ARISTADA® IM (441 mg, 662 mg, 882 ARISTADA® mg, or 1064 mg) Dose Dosage Forms *first dose of ARISTADA® may be given 441 mg ≤6 weeks >6 and ≤7 weeks >7 weeks ARISTADA INITIO® 675 together or within 10 days* 662 mg ≤8 weeks >8 and ≤12 weeks >12 weeks mg pre-filled syringe 882 mg ≤8 weeks >8 and ≤12 weeks >12 weeks ARISTADA® 441
    [Show full text]